Juvéderm Volift reliable in dealing with nasolabial folds up to 1 year

Juvederm Volift with Lidocaine 2ml effectively dealt with moderate-to-severe nasolabial folds up and well-tolerated by people, with results lasting to 1 year, according to research results just recently published in Dermatologic Surgical procedure.

Scientists studied 70 clients (suggest age, 49 years; 94% females) with moderate-to-severe nasolabial folds up (NLF) recruited between June 2012 and January 2013 from 3 facilities in Germany and the Netherlands. All people received initial therapies with the hyaluronic acid facial filler Juvederm Volbella with Lidocaine (VYC-17.5 L, Allergan plc) formulated with 17.5 mg/mL of reduced and high molecular weight hyaluronic acid at baseline (day 0). Twenty-eight clients got top-up therapy on day 14. Follow-ups were at 1, 9 and also twelve months after the last treatment.

Confirmed photonumeric NLF Extent Range was utilized to measure investigator-assessed adjustment in NLF severity over one year, the primary endpoint. People obtained a mean quantity of 3.0 ± 1.0 mL for both nasolabial folds up combined. Sixty-five clients completed the research study.

Investigator-assessed NLF intensity at 12 months saw a significant enhancement, and detectives and individuals reported high satisfaction with the therapy during the study.

Patient-reported discomfort, swelling and bruising generally had low mean ratings after the initial as well as top-up treatments. 2 negative events, consisting of one person with soreness, swelling and also lowered sensitivity, which settled after four days, and also one person with swelling, which resolved after two days, were reported.

” VYC-17.5 L is very efficient in treating moderate-to-severe NLFs with outcomes lasting up to 1 year,” the researchers ended. “As fillers are distinctly suited to deal with certain indicators and areas of the face, visual medical professionals can use the outcomes of this research study to aid develop customized therapy algorithms and lasting therapy plans to achieve optimal treatment results for their clients.”– by Bruce Thiel

Disclosure: Sattler reports being a speaker, study investor, and clinical board of adviser’s participant for Allergan plc, which sponsored the research study. Please see the complete research study for the various other researchers’ appropriate economic disclosures.

Latest Post

Related Post